Andere Sprachen PDS Biotechnology Corporation

Aktien

A2PF3F

US70465T1079

PDSB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.05.2024			% 5 Tage	% 1. Jan.
3,11 ^USD	+0,97 %		-12,64 %	-37,42 %

15.05.	PDS Biotechnology Corporation meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
10.05.	NetScientific sagt, dass Versamune von PDS Biotech die Endpunkte erreicht	AN

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

PDS Biotechnology: Q1 Earnings Snapshot	15.05.
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results	15.05.
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
NetScientific says PDS Biotech's Versamune meets endpoints	10.05.
PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study	10.05.
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer	09.05.
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer	09.05.
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences	09.05.
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024	07.05.
PDS Biotechnology Announces Details of Virtual KOL Event	06.05.
PDS Biotechnology Announces Details of Virtual KOL Event	03.05.
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer	02.05.
PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer	02.05.
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer	24.04.
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer	23.04.
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	28.03.
Empire Metals targets key milestones in Australia	27.03.
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	27.03.
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
North American Morning Briefing : Stocks Edge -2-	27.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PDS Biotechnology Corporation

Aktien

A2PF3F

US70465T1079

PDSB

Andere Sprachen

Filter